Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma

Overview of attention for article published in Frontiers in immunology, December 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 5 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 51,519 followers.

Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma https://t.co/WqO3o5BFsn https://t.co/Biee3WV8GP

11 Dec 2022

Reply Repost Favourite

New Research: Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma: Background Lenvatinib is a standard first-line systemic therapy in advanced… https://t.co/l44F

10 Dec 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.